|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Current assets: | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Short-term investments | |||||||||||||||||
| Nonrelated Party | |||||||||||||||||
| Related Party | |||||||||||||||||
| Total short-term investments | |||||||||||||||||
| Collaboration receivable — related party | |||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||
| Other current assets | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Property and equipment, net | |||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||
| Restricted cash | |||||||||||||||||
| Other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities and Stockholders’ Equity | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Total accounts payable | |||||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||||
| Nonrelated Party | |||||||||||||||||
| Related Party | |||||||||||||||||
| Total accrued expenses and other current liabilities | |||||||||||||||||
| Accrued settlement payment — related party | |||||||||||||||||
| Deferred revenue — related party | |||||||||||||||||
| Operating lease liability | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Deferred revenue, net of current — related party | |||||||||||||||||
| Operating lease liability, net of current | |||||||||||||||||
| Non current deferred tax liability | |||||||||||||||||
| Research and development funding liability | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Redeemable convertible and convertible preferred stock, carrying amount | |||||||||||||||||
| Series A Redeemable Convertible Preferred Stock | |||||||||||||||||
| Series B Convertible Preferred Stock | |||||||||||||||||
| Stockholders’ equity | |||||||||||||||||
| Common stock, par value of $0.00001 per share; 775,000,000 shares authorized; 181,385,357 and 180,514,014 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Accumulated other comprehensive (loss) income | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||||
| Redeemable convertible and convertible preferred stock, shares outstanding (in shares) | |||||||||||||||||
| Series A Redeemable Convertible Preferred Stock | |||||||||||||||||
| Series B Convertible Preferred Stock | |||||||||||||||||
Loading...